Thus, PlGF and the downstream JNK/PKCδ signaling pathways participate in the pathogenesis of CS-related COPD and should be considered potential therapeutic targets for COPD therapy. The gene discussed is PRKCD; the disease is chronic obstructive pulmonary disease.